New cocktail shows promise for Hard-to-Treat lymphoma
NCT ID NCT00428142
First seen Apr 01, 2026 · Last updated May 09, 2026 · Updated 5 times
Summary
This study tested whether adding the drug bortezomib to a standard chemotherapy and antibody combination (BCVP-R) could improve outcomes for people with advanced follicular non-Hodgkin lymphoma who had not yet received treatment. A total of 95 participants were enrolled to see how well the combination worked and what side effects occurred. The goal was to measure complete tumor disappearance and any severe nerve-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1, Canada
-
BCCA - Fraser Valley Cancer Centre
Surrey, British Columbia, V3V 1Z2, Canada
-
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6, Canada
-
BCCA - Vancouver Island Cancer Centre
Victoria, British Columbia, V8R 6V5, Canada
-
CHA-Hopital Du St-Sacrement
Québec, Quebec, G1S 4L8, Canada
-
CHUM - Hopital Notre-Dame
Montreal, Quebec, H2L 4M1, Canada
-
CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9, Canada
-
Credit Valley Hospital
Mississauga, Ontario, L5M 2N1, Canada
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
-
Hopital Charles LeMoyne
Greenfield Park, Quebec, J4V 2H1, Canada
-
Humber River Regional Hospital
Toronto, Ontario, M9N 1N8, Canada
-
London Regional Cancer Program
London, Ontario, N6A 4L6, Canada
-
McGill University - Dept. Oncology
Montreal, Quebec, H2W 1S6, Canada
-
Odette Cancer Centre
Toronto, Ontario, M4N 3M5, Canada
-
QEII Health Sciences Center
Halifax, Nova Scotia, B3H 1V7, Canada
-
Regional Cancer Program of the Hopital Regional
Greater Sudbury, Ontario, P3E 5J1, Canada
-
The Moncton Hospital
Moncton, New Brunswick, E1C 6Z8, Canada
-
Thunder Bay Regional Health Science Centre
Thunder Bay, Ontario, P7B 6V4, Canada
-
Univ. Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.